PREGUNTA FORMULADA


P: Pacientes adultos con espondiloartritis
I: Secukinumab

C: Otros tratamientos disponibles

O: Respuesta clínica, progresión radiológica.

Artículos Propuestos

Proponente Referencia Ver/Descargar
Renan Morales McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2015;386(9999):1137-46.
Eybar Díaz Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. New England Journal of Medicine. 2015;373(14):1329-39.
Jorge Abella Sieper J, Deodhar A. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. 2016.
Eybar Díaz Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. The New England journal of medicine. 2015;373(26):2534-48.
Jorge Abella COSENTYX® Carta de Novartis con la información. ACA RECOPILACION VADEMECUM

Puntos clave/Conclusiones

Pronto.